Field trials with a new genetically engineered vaccine for protection against progressive atrophic rhinitis in pigs.
Field trials were carried out testing a new genetically engineered vaccine against Progressive Atrophic Rhinitis. The vaccine contained a non-toxic recombinant derivative of the P. multocida toxin. The experimental vaccine was compared with a commercial vaccine in 4 farms and in 1 farm 2 different dose regimens were applied. A total of 825 sows were included. The primary efficacy variable was a comparison of post mortem evaluation of the degree of conchae atrophy in the 4585 pigs. The pigs were slaughtered at normal slaughter weight. The secondary efficacy variables were serological response and age at slaughter. In all farms the experimental vaccine provided significantly better protection of the progeny than the control vaccine. The serological response in sows was significantly higher in all farms than the response to the control vaccine. The serological response did not differ between farms.
Bording
A
A
Department of Animal Science and Animal Health, Royal Veterinary and Agricultural University, Copenhagen, Denmark.
Nymark
K
K
Smidt
E
E
D000818:Animals; D000831:Animals, Newborn; D001426:Bacterial Proteins; D001427:Bacterial Toxins / Q000276:immunology; D001428:Bacterial Vaccines; D005260:Female; D016979:Pasteurella multocida / Q000276:immunology*; D012222:Rhinitis, Atrophic / Q000517:prevention & control / Q000662:veterinary*; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*; D014614:Vaccines, Synthetic
D001426:Bacterial Proteins; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; C062258:Pasteurella multocida toxin; D014614:Vaccines, Synthetic